# Nanobiotix S.A.: overview NBTX · Nasdaq · CIK 1760854 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nbtx.md) · [Financials](/companies/nbtx/financials.md) · [Filings](/companies/nbtx/filings.md) · [Insiders](/companies/nbtx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.6](/filings/0001760854-24-000004.md) | [4.8](/filings/0001760854-25-000005.md) | [36.2](/filings/0001760854-26-000003.md) | [(7.2)](/filings/0001760854-26-000003.md) | [32.6](/filings/0001760854-26-000003.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1986.4%)](/filings/0001760854-24-000004.md) | [(977.8%)](/filings/0001760854-25-000005.md) | [(74.0%)](/filings/0001760854-26-000003.md) | [951.1%](/filings/0001760854-26-000003.md) | [(33.2%)](/filings/0001760854-26-000003.md) | | Net margin | % | [(1778.0%)](/filings/0001760854-24-000004.md) | [(1194.3%)](/filings/0001760854-25-000005.md) | [(109.6%)](/filings/0001760854-26-000003.md) | [947.5%](/filings/0001760854-26-000003.md) | [(73.5%)](/filings/0001760854-26-000003.md) | | Diluted EPS | $ per share | [(1.35)](/filings/0001760854-24-000004.md) | [(1.64)](/filings/0001760854-25-000005.md) | [(1.08)](/filings/0001760854-26-000003.md) | [(1.44)](/filings/0001760854-26-000003.md) | [(0.50)](/filings/0001760854-26-000003.md) | | Free cash flow | $m | [(30.1)](/filings/0001760854-24-000004.md) | [(37.2)](/filings/0001760854-25-000005.md) | [(12.8)](/filings/0001760854-26-000003.md) | [(20.4)](/filings/0001760854-26-000003.md) | [(34.0)](/filings/0001760854-26-000003.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nbtx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JOHNSON & JOHNSON](/funds/200406.md) | 2026-06-30 | $212.0m | 5,623,816 | | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.9m | 49,789 | | Added +13,515 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $1.2m | 32,180 | | New +32,180 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $597.7k | 15,855 | | New +15,855 | | [Optiver Holding B.V.](/funds/1859606.md) | 2026-06-30 | $513.9k | 13,631 | | Added +130 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $378.7k | 10,044 | | Added +805 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $227.8k | 6,042 | | New +6,042 | | [BNP PARIBAS FINANCIAL MARKETS](/funds/1166588.md) | 2026-06-30 | $152.5k | 4,044 | | Added +485 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $97.2k | 2,577 | | Reduced −2,980 | | [ROYAL BANK OF CANADA](/funds/1000275.md) | 2026-06-30 | $83.0k | 2,189 | | Added +364 | ## Recent filings [All 307 filings](/companies/nbtx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 16:15 ET | [6-K](/filings/0001171843-26-006721.md) | Report of a foreign private issuer, period 2026-10-20 | 0001171843-26-006721 | | 2026-10-01 | 16:30 ET | [6-K](/filings/0001171843-26-006335.md) | Report of a foreign private issuer, period 2026-10-01 | 0001171843-26-006335 | | 2026-09-24 | 16:17 ET | [6-K](/filings/0001760854-26-000006.md) | Report of a foreign private issuer, period 2026-06-30 | 0001760854-26-000006 | | 2026-09-24 | 16:15 ET | [6-K](/filings/0001171843-26-006217.md) | Report of a foreign private issuer, period 2026-09-24 | 0001171843-26-006217 | | 2026-09-22 | 16:15 ET | [6-K](/filings/0001171843-26-006172.md) | Report of a foreign private issuer, period 2026-09-22 | 0001171843-26-006172 | | 2026-09-14 | 06:00 ET | [6-K](/filings/0001171843-26-006011.md) | Report of a foreign private issuer, period 2026-09-14 | 0001171843-26-006011 | | 2026-09-09 | 16:17 ET | [6-K](/filings/0001171843-26-005955.md) | Report of a foreign private issuer, period 2026-09-09 | 0001171843-26-005955 | | 2026-08-25 | 16:15 ET | [6-K](/filings/0001171843-26-005734.md) | Report of a foreign private issuer, period 2026-08-25 | 0001171843-26-005734 | | 2026-07-31 | 17:13 ET | [6-K](/filings/0001171843-26-005120.md) | Report of a foreign private issuer, period 2026-07-30 | 0001171843-26-005120 | | 2026-06-05 | 16:15 ET | [6-K](/filings/0001171843-26-003942.md) | Report of a foreign private issuer, period 2026-06-05 | 0001171843-26-003942 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001760854-26-000003.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1760854 - Tickers: NBTX, NNBXF - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: I0 - Filer category: Accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 06:02 ET. No prices; not investment advice.